High-throughput virtual screening to identify potential small molecule inhibitors of the Zα domain of the adenosine deaminases acting on RNA 1(ADAR1)
Copyright © 2023 The Author(s). Published by Elsevier B.V. All rights reserved..
Changes in RNA editing are closely associated with diseases such as cancer, viral infections, and autoimmune disorders. Adenosine deaminase (ADAR1), which acts on RNA 1, plays a key role in adenosine to inosine editing and is a potential therapeutic target for these various diseases. The p150 subtype of ADAR1 is the only one that contains a Zα domain that binds to both Z-DNA and Z-RNA. The Zα domain modulates immune responses and may be suitable targets for antiviral therapy and cancer immunotherapy. In this study, we attempted to utilize molecular docking to identify potential inhibitors that bind to the ADAR1 Zα domain. The virtual docking method screened the potential activity of more than 100,000 compounds on the Zα domain of ADAR1 and filtered to obtain the highest scoring results.We identified 71 compounds promising to bind to ADAR1 and confirmed that two of them, lithospermic acid and Regaloside B, interacts with the ADAR1 Zα domain by surface plasmonic resonance technique. The molecular dynamics calculation of the complex of lithospermic acid and ADAR1 also showed that the binding effect of lithospermic acid to ADAR1 was stable.This study provides a new perspective for the search of ADAR1 inhibitors, and further studies on the anti-ADAR11 activity of these compounds have broad prospects.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:193 |
|---|---|
| Enthalten in: |
European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences - 193(2024) vom: 01. Jan., Seite 106672 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Hong, Xiaoshan [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 22.01.2024 Date Revised 22.01.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.ejps.2023.106672 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM365943576 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM365943576 | ||
| 003 | DE-627 | ||
| 005 | 20240122232005.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231227s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.ejps.2023.106672 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1267.xml |
| 035 | |a (DE-627)NLM365943576 | ||
| 035 | |a (NLM)38103658 | ||
| 035 | |a (PII)S0928-0987(23)00300-7 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Hong, Xiaoshan |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a High-throughput virtual screening to identify potential small molecule inhibitors of the Zα domain of the adenosine deaminases acting on RNA 1(ADAR1) |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 22.01.2024 | ||
| 500 | |a Date Revised 22.01.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2023 The Author(s). Published by Elsevier B.V. All rights reserved. | ||
| 520 | |a Changes in RNA editing are closely associated with diseases such as cancer, viral infections, and autoimmune disorders. Adenosine deaminase (ADAR1), which acts on RNA 1, plays a key role in adenosine to inosine editing and is a potential therapeutic target for these various diseases. The p150 subtype of ADAR1 is the only one that contains a Zα domain that binds to both Z-DNA and Z-RNA. The Zα domain modulates immune responses and may be suitable targets for antiviral therapy and cancer immunotherapy. In this study, we attempted to utilize molecular docking to identify potential inhibitors that bind to the ADAR1 Zα domain. The virtual docking method screened the potential activity of more than 100,000 compounds on the Zα domain of ADAR1 and filtered to obtain the highest scoring results.We identified 71 compounds promising to bind to ADAR1 and confirmed that two of them, lithospermic acid and Regaloside B, interacts with the ADAR1 Zα domain by surface plasmonic resonance technique. The molecular dynamics calculation of the complex of lithospermic acid and ADAR1 also showed that the binding effect of lithospermic acid to ADAR1 was stable.This study provides a new perspective for the search of ADAR1 inhibitors, and further studies on the anti-ADAR11 activity of these compounds have broad prospects | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a ADAR1 | |
| 650 | 4 | |a ADAR1 inhibitors | |
| 650 | 4 | |a High-throughput screening | |
| 650 | 4 | |a Molecular docking | |
| 650 | 4 | |a Molecular dynamics simulation | |
| 650 | 4 | |a Surface plasmon resonance | |
| 650 | 7 | |a lithospermic acid |2 NLM | |
| 650 | 7 | |a 100IP83JAC |2 NLM | |
| 650 | 7 | |a RNA |2 NLM | |
| 650 | 7 | |a 63231-63-0 |2 NLM | |
| 650 | 7 | |a Adenosine Deaminase |2 NLM | |
| 650 | 7 | |a EC 3.5.4.4 |2 NLM | |
| 650 | 7 | |a Benzofurans |2 NLM | |
| 650 | 7 | |a Depsides |2 NLM | |
| 700 | 1 | |a Wei, Zhifu |e verfasserin |4 aut | |
| 700 | 1 | |a He, Lulu |e verfasserin |4 aut | |
| 700 | 1 | |a Bu, Qiaowen |e verfasserin |4 aut | |
| 700 | 1 | |a Wu, Guosong |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Guanqiao |e verfasserin |4 aut | |
| 700 | 1 | |a He, Wanshan |e verfasserin |4 aut | |
| 700 | 1 | |a Deng, Qiuhua |e verfasserin |4 aut | |
| 700 | 1 | |a Huang, Shiqi |e verfasserin |4 aut | |
| 700 | 1 | |a Huang, Yongmei |e verfasserin |4 aut | |
| 700 | 1 | |a Yu, Cai |e verfasserin |4 aut | |
| 700 | 1 | |a Luo, Xiping |e verfasserin |4 aut | |
| 700 | 1 | |a Lin, Yu |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences |d 1998 |g 193(2024) vom: 01. Jan., Seite 106672 |w (DE-627)NLM097331937 |x 1879-0720 |7 nnns |
| 773 | 1 | 8 | |g volume:193 |g year:2024 |g day:01 |g month:01 |g pages:106672 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.ejps.2023.106672 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 193 |j 2024 |b 01 |c 01 |h 106672 | ||